Antifungal effect of solid lipid nanoparticles loaded with atorvastatin against candida yeast species as the most common cause of denture stomatitis

Articles in Press

Document Type : Research Paper

Authors

1 Department of Oral Medicine, Dental Research Center, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran

2 Pharmaceutical Sciences Research Center, Haemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.

3 Department of Pharmaceutics, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

4 Student Research Committee, Dental Research Committee, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran.

5 Department of Pharmaceutics, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

6 Department of Oral and Maxillofacial Surgery, Dental Research Center, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran

7 Department of Prosthodontics, Dental Research Center, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran

8 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.

9 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

10 Department of Periodontology, Faculty of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): Statins have been used to treat denture stomatitis due to their antifungal properties. However, the side effects associated with these drugs have limited their broader application. This study aimed to evaluate the antifungal effects of solid lipid nanoparticles (SLNs) loaded with atorvastatin (AT-SLN) against the most common Candida species, Candida albicans and Candida glabrata, which are frequently implicated in denture stomatitis.
Materials and Methods: AT-SLN was synthesized using an ultrasonication method in this experimental study. The minimum inhibitory concentrations (MICs) of 11 C. albicans and 5 C. glabrata isolates were determined against AT-SLN, atorvastatin (AT), and nystatin (NYS), following the Clinical & Laboratory Standards Institute (CLSI) guidelines (M27-A3 and M27-S4).
Results: The results showed that AT-SLN exhibited the lowest polydispersity index with the optimal hydrophilic-lipophilic balance. Significant differences were observed in the MICs of AT-SLN, AT, and NYS against both C. albicans (P<0.001) and C. glabrata (P = 0.005) isolates. AT-SLN-treated isolates demonstrated significantly reduced MICs (P<0.001). No significant differences were found in the inhibitory effects of AT (P=0.542) and NYS (P=0.526) between C. albicans and C. glabrata.
Conclusion: The findings suggest that AT-SLN may represent a promising antifungal agent for treating denture stomatitis. Further in vivo studies are warranted to confirm these results.

Keywords

References

  1. Ramezani A, Mollaei M, Yazdani Charati J, Tavakolian H, Mesgarani A, Molania T. Prevalence of Denture Stomatitis in Patients Using Denture in Sari City, Iran, in 2020-2021. Iran J Health Sci. 2023;11(2):137-142.
  2. Gendreau L, Loewy ZG. Epidemiology and etiology of denture stomatitis. J Prosthodont. 2011;20(4):251-260.
  3. Dadar M, Tiwari R, Karthik K, Chakraborty S, Shahali Y, Dhama K. Candida albicans-Biology, molecular characterization, pathogenicity, and advances in diagnosis and control–An update. Microb Pathog. 2018;117:128-138.
  4. Fakhra DI. Comparison Of The Efficacy And Tolerance Between Miconazole As Chewing Gum And As Gel Application In Patients With Oral Candidiasis. Doctoral dissertation, Bbdcods. 2021.
  5. Abuhajar E, Ali K, Zulfiqar G, Al Ansari K, Raja HZ, Bishti S, et al. Management of Chronic Atrophic Candidiasis (Denture Stomatitis)—A Narrative Review. Int J Environ Res Public Health. 2023;20(4):3029.
  6. Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: pros and cons. Med Clin (English Edition). 2018;150(10):398-402.
  7. Sadowska A, Osiński P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D, et al. Statins—From Fungi to Pharmacy. Int J Mol Sci. 2023;25(1):466.
  8. Esfahani AN, Golestannejad Z, Khozeimeh F, Dehghan P, Maheronnaghsh M, Zarei Z. Antifungal effect of Atorvastatin against Candida species in comparison to Fluconazole and Nystatin. Med Pharm Rep. 2019;92(4):368.
  9. Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019;124(2):328-350.
  10. Etemad L, Salmasi Z, Kalat SAM, Moshiri M, Zamanian J, Kesharwani P, et al. An overview on nanoplatforms for statins delivery: Perspective study for safe and effective therapy methods. Environ Res. 2023:116572.
  11. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):1-29.
  12. Dikmen G, Genç L, Güney G. Advantage and disadvantage in drug delivery systems. J Mater Eng. 2011;5(4):468.
  13. Moaddabi A, Soltani P, Rengo C, Molaei S, Mousavi SJ, Mehdizadeh M, et al. Comparison of antimicrobial and wound-healing effects of silver nanoparticle and chlorhexidine mouthwashes: An in vivo study in rabbits. Odontology. 2022;110(3):577-583.
  14. Korani S, Korani M, Bahrami S, Johnston TP, Butler AE, Banach M, et al. Application of nanotechnology to improve the therapeutic benefits of statins. Drug Discov. Today. 2019;24(2):567-574.
  15. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv Rev. 2012;64:83-101.
  16. Kakadia PG, Conway BR. Solid lipid nanoparticles: a potential approach for dermal drug delivery. Am J Pharmacol Sci. 2014;2(5A).
  17. Sathali A, Ekambaram P, Priyanka K. Solid lipid nanoparticles: a review. Sci. Rev. Chem. Commun. 2012;2(1):80-102.
  18. Shahraeini SS, Akbari J, Saeedi M, Morteza-Semnani K, Abootorabi S, Dehghanpoor M, et al. Atorvastatin solid lipid nanoparticles as a promising approach for dermal delivery and an anti-inflammatory agent. AAPS Pharm Sci Tech. 2020;21(7):1-10.
  19. Boskabadi M, Saeedi M, Akbari J, Morteza-Semnani K, Hashemi SMH, Babaei A. Topical Gel of Vitamin A Solid Lipid Nanoparticles: A Hopeful Promise as a Dermal Delivery System. Adv Pharm Bull. 2021;11(4):663.
  20. Saeedi M, Morteza-Semnani K, Akbari J, Siahposht-Khachaki A, Firouzi M, Goodarzi A, et al. Brain targeting of venlafaxine HCl as a hydrophilic agent prepared through green lipid nanotechnology. J Drug Deliv Sci Technol. 2021;66:102813.
  21. Enayatifard R, Akbari J, Saeedi M, Morteza-Semnani K, Parvin S, Hashemi MH, et al. Investigating the effect of coated lipid nano particles of spironolactone with chitosan on their properties. J Mazandaran Univ Med Sci. 2018;28(162):25-36.
  22. Rahimzadeh G, Saeedi M, Moosazadeh M, Hashemi SMH, Babaei A, Rezai MS, et al. Encapsulation of bacteriophage cocktail into chitosan for the treatment of bacterial diarrhea. Sci Rep. 2021;11(1):1-10.
  23. Morteza-Semnani K, Saeedi M, Akbari J, Eghbali M, Babaei A, Hashemi SMH, et al. Development of a novel nanoemulgel formulation containing cumin essential oil as skin permeation enhancer. Drug Deliv Transl Res. 2022;12(6):1455-1465.
  24. Abootorabi S, Akbari J, Saeedi M, Seyedabadi M, Ranaee M, Asare-Addo K, et al. Atorvastatin entrapped noisome (atrosome): green preparation approach for wound healing. AAPS Pharm Sci Tech. 2022;23(3):81.
  25. Morteza-Semnani K, Saeedi M, Akbari J, Moazeni M, Seraj H, Daftarifard E, et al. Fluconazole nanosuspension enhances in vitro antifungal activity against resistant strains of Candida albicans. Pharm Sci. 2021.
  26. Saeedi M, Akbari J, Semnani K, Hashemi SMH, Ghasemi S, Tahmasbi N, et al. Controlling atorvastatin release from liquisolid systems. J Dispers Sci Technol. 2022;43(3):375-384.
  27. Hashemi SMH, Enayatifard R, Akbari J, Saeedi M, Seyedabadi M, Morteza-Semnani K, et al. Venlafaxine HCl Encapsulated in Niosome: Green and Eco-friendly Formulation for the Management of Pain. AAPS Pharm Sci Tech. 2022;23(5):149.
  28. Akbari J, Saeedi M, Morteza-Semnani K, Hashemi SMH, Babaei A, Eghbali M, et al. Innovative topical niosomal gel formulation containing diclofenac sodium (niofenac). J Drug Res. 2022;30(1):108-117.
  29. Wayne P. Clinical and Laboratory Standards Institute (CLSI): Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Carol Stream, IL: Allured Publ. Corp. 2008.
  30. Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25(1).
  31. Çelik H, Karahan H, Kelicen-Uğur P. Effect of atorvastatin on Aβ1–42-induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures. J Pharm Pharmacol. 2020;72(3):424-436.
  32. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett. 2006;262(1):9-13.
  33. Radmard A, Saeedi M, Morteza-Semnani K, Hashemi SMH, Nokhodchi A. An eco-friendly and green formulation in lipid nanotechnology for delivery of a hydrophilic agent to the skin in the treatment and management of hyperpigmentation complaints: Arbutin niosome (Arbusome). Colloids Surf B Biointerfaces. 2021;201:111616.
  34. Attwood D, Florence AT. "Physical Pharmacy: Fast Track." Pharm. Press (2008).
  35. Shahraeini SS, Akbari J, Saeedi M, Morteza-Semnani K, Abootorabi S, Dehghanpoor M, et al. Atorvastatin solid lipid nanoparticles as a promising approach for dermal delivery and an anti-inflammatory agent. AAPS Pharm Sci Tech. 2020;21:1-10.
  36. Rostamkalaei SS, Akbari J, Saeedi M, Morteza-Semnani K, Nokhodchi A. Topical gel of Metformin solid lipid nanoparticles: A hopeful promise as a dermal delivery system. Colloids Surf B Biointerfaces. 2019;175:150-157.
  37. Avadi MR, Sadeghi AMM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R, et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomed. Nanotechnol. Biol Med. 2010;6(1):58-63.
  38. Silva LAB, Novaes Jr AB, de Oliveira RR, Nelson-Filho P, Santamaria Jr M, Silva RAB. Antimicrobial photodynamic therapy for the treatment of teeth with apical periodontitis: a histopathological evaluation. J Endod. 2012;38(3):360-366.
  39. Abismaıl B, Canselier JP, Wilhelm AM, Delmas H, Gourdon C. Emulsification by ultrasound: drop size distribution and stability. Ultrason. Sonochem. 1999;6(1-2):75-83.
  40. Suh H, Jun HW, Dzimianski M, Lu G. Pharmacokinetic and local tissue disposition studies of naproxen following topical and systemic administration in dogs and rats. Biopharm Drug Dispos. 1997;18(7):623-633.
  41. Wingfield J, Badcott D, Appelbe GE. Pharmacy ethics and decision making. Pharm Press London. 2007.
  42. Diril M, Karasulu Y, Toskas M, Nikolakakis I. Development and permeability testing of self-emulsifying atorvastatin calcium pellets and tablets of compressed pellets. Processes. 2019;7(6):365.
  43. Kheradmandnia S, Vasheghani FE, Nosrati M, Atyabi F. The effect of process variables on the properties of ketoprofen loaded solid lipid nanoparticles of beeswax and carnauba wax. 2010.
  44. Trivino A, Gumireddy A, Chauhan H. Drug-lipid-surfactant miscibility for the development of solid lipid nanoparticles. AAPS Pharm Sci Tech. 2019;20(2):1-9.
  45. Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Appl Nanosci. 2017;7(1):47-57.
  46. Müller R, Runge S, Ravelli V, Thünemann AF, Mehnert W, Souto E. Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug–lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm. 2008;68(3):535-544.
  47. Nath B, Roy T. Thermal characterization and screening of formulation variables of atorvastatin calcium immediate release tablet. JSM Nanotechnol. Nanomed. 2017;5(1):1044-1052.
  48. Kelidari H, Saeedi M, Akbari J, Morteza-Semnani K, Gill P, Valizadeh H, et al. Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2015;128:473-479.
  49. Yarborough A, Cooper L, Duqum I, Mendonça G, McGraw K, Stoner L. Evidence regarding the treatment of denture stomatitis. J Prosthodont. 2016;25(4):288-301.
  50. Morsy MA, Abdel-Latif RG, Nair AB, Venugopala KN, Ahmed AF, Elsewedy HS, et al. Preparation and evaluation of atorvastatin-loaded nanoemulgel on wound-healing efficacy. Pharm. 2019;11(11):609.
  51. Lima WG, Alves-Nascimento LA, Andrade JT, Vieira L, de Azambuja Ribeiro RIM, Thome RG, et al. Are the Statins promising antifungal agents against invasive candidiasis?. Biomed Pharmacother. 2019;111:270-81.
  52. Nyilasi I. Effect of different statins on the antifungal activity of polyene antimycotics. Acta Biol Szeged. 2010;54(1):33-36.
  53. Bakhtiari S, Jafari S, Taheri JB, Kashi TSJ, Namazi Z, Iman M, et al. The effects of cinnamaldehyde (Cinnamon derivatives) and nystatin on candida albicans and candida glabrata. Open Access Maced. J Med Sci. 2019;7(7):1067.
  54. Brilhante RSN, Fonseca XMQC, Pereira VS, dos Santos Araújo G, de Oliveira JS, Garcia LGS, et al. In vitro inhibitory effect of statins on planktonic cells and biofilms of the Sporothrix schenckii species complex. J Med Microbiol. 2020;69(6):838-843.
  55. Nagpal A, Kaur J, Sharma S, Bansal A, Sachdev P. Nanotechnology-the Era Of Molecular Dentistry. Indian J Dent Sci. 2011;3(5).
  56. Yue X, Niu M, Zhang T, Wang C, Wang Z, Wu W, et al. In vivo evaluation of a simvastatin-loaded nanostructured lipid carrier for bone tissue regeneration. Nanotechnol. 2016;27(11):115708.
  57. Rodrigues DF, Couto ROd, Sinisterra RD, Jensen CEdM. Novel Eudragit®-based polymeric nanoparticles for sustained release of simvastatin. Braz J Pharm Sci. 2020;56.
  58. Lefebvre M, Alshawa K, Dupont B. Antifungal activity of statins. J Mycol Med. 2010;20(3):212-217.

 

 

Nanomedicine Journal

Articles in Press, Accepted Manuscript
Available Online from 23 June 2025

Files

Share

How to cite

Statistics